Short Interest in NuCana plc (NASDAQ:NCNA) Drops By 15.7%

NuCana plc (NASDAQ:NCNA) was the recipient of a large drop in short interest in the month of January. As of January 15th, there was short interest totalling 121,700 shares, a drop of 15.7% from the December 31st total of 144,300 shares. Based on an average daily trading volume, of 149,300 shares, the short-interest ratio is currently 0.8 days. Currently, 3.3% of the company’s stock are sold short.

NuCana Trading Down 1.0 %

Shares of NASDAQ NCNA traded down $0.01 during midday trading on Friday, reaching $1.02. The company’s stock had a trading volume of 135,153 shares, compared to its average volume of 89,415. The stock has a 50 day simple moving average of $1.21 and a 200-day simple moving average of $2.44. NuCana has a fifty-two week low of $0.85 and a fifty-two week high of $19.41. The stock has a market capitalization of $2.69 million, a price-to-earnings ratio of -0.10 and a beta of 0.97.

NuCana (NASDAQ:NCNA) last issued its quarterly earnings data on Monday, November 25th. The company reported ($2.28) earnings per share for the quarter, beating the consensus estimate of ($3.49) by $1.21. As a group, equities analysts anticipate that NuCana will post -12.86 EPS for the current year.

About NuCana

NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of medicines to treat patients with cancer. It applies its ProTide technology to transform prescribed chemotherapy agents and nucleoside analogs into medicines. The company, through its technology, is developing ProTides medicines to overcome the limitations of nucleoside analogs and generate much higher concentrations of anti-cancer metabolites in cancer cells.